drugset / Trial / NCT03680417
Reactogenicity and Protectivity Following Measles- Rubella (MR) Routine Immunization in Indonesian Infants and Children
RandomizedParallel-groupSingle-blindPrevention
Summary
to assess safety and immunogenicity of measles-rubella (MR) routine immunization in Indonesian Children and Infants
Timeline
- Start
- 2017-11-16
- Primary completion
- 2018-02-26
- Completion
- 2018-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Measles-Rubella (MR) Vaccine | Vaccine | 0.5 ml | — |
Indications
No indication recorded.